Valuation: Axsome Therapeutics, Inc.

Market Cap 8.47B 7.53B 6.98B 6.35B 11.99B 804B 12.18B 83.93B 32.91B 420B 31.81B 31.13B 1,338B P/E 2026 *
-56x
P/E 2027 * 39.4x
Enterprise Value 8.33B 7.4B 6.86B 6.24B 11.78B 790B 11.97B 82.47B 32.33B 412B 31.25B 30.59B 1,315B EV / Sales 2026 *
8.74x
EV / Sales 2027 * 5.3x
Free-Float
84.69%
Yield 2026 *
-
Yield 2027 * -
1 day-2.40%
1 week-6.35%
Current month-14.50%
1 month-25.62%
3 months-33.49%
6 months-14.40%
Current year-13.68%
1 week 155.18
Extreme 155.1801
170.8
1 month 155.18
Extreme 155.1801
216.47
Current year 152.28
Extreme 152.28
260.19
1 year 123.5
Extreme 123.5
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 20.63
Extreme 20.63
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 11/01/2012
Director of Finance/CFO 51 15/05/2018
Chief Operating Officer 42 31/03/2014
Director TitleAgeSince
Chairman 57 11/01/2012
Director/Board Member 64 30/11/2014
Director/Board Member 58 30/11/2014
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Exercice

Chief Operating Officer

30,000 0.0573%
06/08/26 Exercice

Chief Executive Officer

13,980 0.0272%
01/07/26 Exercice

Chief Executive Officer

148,998 0.2895%
Change 5-day change 1-year change 3-year change Capi.($)
-2.40%-6.35%+26.13%+135.63% 8.47B
+0.30%+6.33%+53.04%+103.35% 1,116B
+0.79%-2.28%+32.97%+62.17% 610B
+0.72%+3.26%+25.83%+93.90% 501B
+0.79%+0.37%+74.14%+40.33% 358B
-0.13%+5.98%+32.91%+50.39% 366B
-0.95%+4.70%+19.51%+43.00% 288B
-1.98%+3.73%-0.86%+13.43% 261B
-0.52%+4.26%+46.22%+50.77% 235B
-0.98%+3.15%+32.31%+96.88% 195B
Average -0.47%+4.25%+34.22%+68.99% 393.82B
Weighted average by Cap. +0.07%+4.91%+39.00%+71.36%

Financials

2026 *2027 *
Net sales 953M 847M 785M 714M 1.35B 90.41B 1.37B 9.43B 3.7B 47.18B 3.57B 3.5B 150B 1.52B 1.35B 1.25B 1.14B 2.15B 144B 2.18B 15.04B 5.9B 75.21B 5.7B 5.58B 240B
Net income -152M -135M -125M -114M -215M -14.42B -218M -1.5B -590M -7.53B -570M -558M -23.99B 222M 197M 183M 166M 314M 21.04B 319M 2.2B 861M 10.98B 832M 814M 35B
Net Debt -148M -131M -122M -111M -209M -14.01B -212M -1.46B -573M -7.31B -554M -542M -23.3B -421M -374M -347M -316M -596M -39.96B -605M -4.17B -1.63B -20.85B -1.58B -1.55B -66.47B
Projected Income Statement - Annual - Axsome Therapeutics, Inc.
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,346
Date Price Change Volume
16/10/26 US$157.13 -2.88% 459,039
15/10/26 US$161.79 -0.27% 802,617
14/10/26 US$162.22 +3.77% 893,237
13/10/26 US$156.32 -5.83% 1,328,730
12/10/26 US$166.00 -1.40% 663,002
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Axsome Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
161.79USD
Average target price
282.54USD
Spread / Average Target
+74.63%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Axsome Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. AXSM Stock